Skip to main content

Table 1 Stage 1 and 2 genotype results for SNPs achieving uncorrected P-value ≤ 0.05 in stage 1 analysis

From: Addressing the contribution of previously described genetic and epidemiological risk factors associated with increased prostate cancer risk and aggressive disease within men from South Africa

  

Stage 1 (179 cases, 144 controls)

Stage 2 (297 cases, 206 controls)

Marker (risk allele)

Location

MAF cases

MAF controls

OR (95% CI)

P-value

MAF cases

MAF controls

OR (95% CI)

P-value

rs6983561 (C)

8q24 region 2

0.478

0.372

1.54 (1.12-2.13)

0.0094

0.505

0.407

1.45 (1.15-1.92)

0.0024

rs1859962 (G)

17q24

0.270

0.197

1.50 (1.03-2.20)

0.0379

0.260

0.199

1.42 (1.05-1.93)

0.0276

rs13254738 (C)

8q24 region 2

0.331

0.416

0.70 (0.50-0.96)

0.0306

0.323

0.389

0.75 (0.58-0.98)

0.0363

rs10090154 (T)

8q24 region 1

0.138

0.226

0.55 (0.36-0.83)

0.0044

0.167

0.212

0.74 (0.54-1.03)

0.0815

rs4242382 (A)

8q24 region 1

0.253

0.325

0.07 (0.50-1.00)

0.0503

0.269

0.299

0.87 (0.66-1.44)

0.3189

rs1465618 (A)

2p21

0.118

0.069

1.80 (1.02-3.16)

0.0423

0.098

0.081

1.23 (0.79-1.92)

0.4336

  1. Stage 1 and stage 2 association analysis with over-all prostate cancer risk was achieved by comparing minor allele frequencies (MAF) in cases versus controls. Allelic odds ratios (OR) and 95% confidence intervals (CI) were estimated using logistic regression models. We report un-corrected P-values derived using Fischer’s exact test. Association results for alleles achieving un-corrected P-value < 0.05 are represented in bold type.
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us